Conference Talk

Technologies to Improve Solubility/Dissolution Rate and Oral Bioavailability of Poorly Soluble Drugs

Sudhakar Garad
Sudhakar Garad, Global Head, Chemical and Pharmaceutical Profiling, Novartis

Talk Abstract: Dosage form (formulation) and enabling technologies to play a vital role in the success of new chemical entities transitioning from preclinical to clinical development through commercialization. The majority of new chemical entities being discovered in many disease areas have a poor aqueous and bio-relevant solubility. These are often available in the amorphous and chemically impure form of in-vitro enzyme assays, pharmacokinetic, pharmacological and toxicological studies in animal models.  These molecules are often dosed as a suspension/solution orally/parenterally respectively and candidate selection is based on results obtained from these studies. Therefore, it is very important to select a physical form as early as possible so that the same form can be used for preclinical and clinical studies, as changes in physical form or formulation principle could significantly affect the pharmacokinetic performance and formulation characteristics (i.e. stability/solubility/compatibility) and toxicity. The selected candidate must exhibit adequate physical and chemical stability during the formulation development process with desirable pharmacokinetic parameters. If pharmacokinetics parameters of these molecules are different due to different physical form or formulation selection, a significant delay may occur during development. It’s important to explore enabling technologies with existing molecules depending on the clinical/market need.  This presentation will cover early formulation strategies and novel technologies to improve the bioavailability of poorly soluble drugs.

Let us meet and see what new technologies Dr Sudhakar Garad, from Novartis, USA wishes to share with us. Register today for Novel Formulation Strategies

For more details, please contact Ms Shivalika Patial by Email – s.patial@selectbio.in or Call at 8283815050 or Whatsapp at 9041725050

Advertisements

Conference Talk

CRO-Sponsor collaboration, a different way is possible

Dr Diego Herrera
Dr Diego Herrera, Almirall, Spain

There is no reason to be afraid of  CRO-Sponsor collaboration as, it started a long time ago in the late 1970s, so this relationship is nothing new. Additionally, CRO and Sponsor are sharing common goals to promote, conduct, oversight and ensure the compliance of a broad range of clinical trials type, data sources with high-quality evidence.

CRO-Sponsor evolved over the years because of continuous changes in the company ’s strategies, reorganizations, and growing clinical trials digitalization. The guidelines/regulations introduced by regulatory authorities have also played an important role in setting up of new services and business models, expanding the CRO-Sponsor collaboration horizon.

Transparency leads to a better collaboration. CRO-Sponsor should start early to design common plans for the entire study,  review these plans and patient data dynamically during the study to ensure final data integrity. Sponsor oversight is not only nice to have, it is actually mandated.

From the Sponsor and Data Management perspective, Dr. Diego Herrera in his presentation will be touching upon ongoing Regulatory and Market initiatives, current Clinical Outsourcing Drivers,  Common Issues, Emerging Trends and Organizational Changes to understand a different outlook at CRO-Sponsor collaboration.

Dr. Herrera’s current position is Head Global Data Management and Project Information, he is managing one senior team mainly focused to ensure document and data integrity in Clinical Trials and oversight CROs activities and services.

You can have his perspective @CRO/Sponsor Summit on Data Integrity “Quality, Compliance and Audit in Clinical Trials” #CROIn18.

Identification of Non-canonical (India-specific) Genetic Alterations in Colorectal Cancer Using Next Generation Sequencing

Conference talk by Dr. Murali Bashyam

bashyam
Dr. Murali Dharan Bashyam, Head, Lab of molecular oncology

Talk Abstract: Colorectal Cancer (CRC) is a lifestyle associated disease and a major health problem in the Caucasian population, where it is primarily aging-related cancer with tumors predominantly arising from the colon rather than the rectum. In addition, aberrant constitutive activation of the Wnt signaling cascade causing chromosomal instability (CIN) and mismatch repair (MMR) inactivation leading to microsatellite instability are major drivers of CRC in the West.India has seen a recent rapid rise in CRC incidence during the past 2-3 decades probably owing to rapid urbanization. In contrast to the West, however, CRC in India often occurs in younger individuals with tumors localized to the rectum rather than the colon. Thus, early-onset rectal cancer (EORC) is the predominant but poorly understood CRC subtype in India. We performed a comprehensive evaluation of more than one thousand sporadic CRC samples from Indian patients that revealed distinct clinicopathological and biological features. More importantly, a significant proportion of EORC tumors appeared to be devoid of activated Wnt signaling and MMR inactivation. Genome-wide DNA copy number profiling revealed extensive CIN in both Wnt+ and Wnt- tumors. Transcriptome profiling (using microarrays as well as next-generation sequencing) revealed a (non-Wnt) gene signature surprisingly harboring genes related to the Ca2+/NFAT pathway enriched specifically in Wnt- EORC. Separately, we performed mutation profiling (using next-generation exome sequencing) of Wnt- EORC samples revealing known (APC, KRAS, P53, PIK3CA) and novel frequently mutated genes. Surprisingly, we identified APC mutations in the absence of Wnt activation indicating a possible non-canonical role for APC in CRC. Our study has, therefore, revealed several unique genetic aberrations distinct from the West that drive CRC in India.

 

Dr. Murali Dharan Bashyam is Head, Lab of molecular oncology CDFD, Hyderabad

Meet Dr. Bashyam on November 1, 2017, in Mumbai, India at Emerging Role of Next Generation Sequencing in Clinical Genomics.

Targeted NGS of Solid Tumors via Liquid Biopsy Providing an Accurate Snapshot of Cancer

Conference talk by Dr. Urvashi

URVASHI bHADUR
Dr. Urvashi Bahadur, Vice President-Clinical Diagnostics, Strand Life Sciences

Talk Abstract: The latest technique to identify and monitor the genetic signature of different types of Cancer, that the medical fraternity is warming up to is a Liquid Biopsy test. Essentially, these tests are a set of new blood tests that enable scientists to extract and analyze DNA shed by cancer cells in a patient’s blood. The presence or absence and the concentration of characteristic mutations in the liquid biopsy provide an accurate snapshot of cancer.  A unique feature of these tests is that these are not ‘one size fits all’ kind of tests. Liquid biopsy tests are personalized tests that are modified to track cancer in each patient in a specific fashion.Genomic profiling of a tumor derived from a liquid biopsy can provide valuable insight into its biology. Next Generation Sequencing (NGS) can simultaneously profile tumors for multiple, therapeutically relevant mutations with far greater sensitivity than other conventional sequencing methods. Results of such testing clubbed together can also suggest a good treatment plan and novel therapeutic approaches indicating the response to a drug approved for other tumor types or drugs in trials.  The liquid biopsy allows for profiling via detection of traces of tumor DNA in the blood of an individual and  is fruitful in investigating new changes in a tumor, such as the development of acquired resistance or recurrence, it provides insights to assess if a patient is prone to a relapse and if a person is likely to respond to therapy or not.

These topics will be discussed in detail in the presentation.

Dr. Urvashi Bahadur is Vice President-Clinical Diagnostics, Strand Life Sciences Meet Dr. Urvashi Bahadur on November 1, 2017, in Mumbai, India at Emerging Role of Next Generation Sequencing in Clinical Genomics.

 

NGS for Inherited Retinal Disorders-Poised to become a Clinical Reality

Conference Talk by Dr. Chakrabarti

dr subho
Dr. Subhabrata Chakrabarti, Associate Director-Research, LVPEI

Talk Abstract: Recent advances in genome analyses have resulted in a plethora of information on gene functions in single-gene disorders, but our knowledge on multi-gene involvement in disease manifestation is limited. The rapid advancement of technologies in understanding the genome have further facilitated in providing insights into the underlying molecular mechanisms leading to disease pathogenesis. There are several ocular diseases that manifest simple to complex etiologies and affects humans of all ages. The development of next-generation sequencing (NGS) technology has facilitated novel gene discoveries, a better appreciation of gene-gene interactions that have led to the identification of modifier genes. Using the scenario of Mendelian and complex eye diseases, I shall demonstrate the advances that we have made in this field pertaining to the understanding of the molecular etiology in facilitating better disease management. I will also provide some novel molecular mechanisms in glaucoma (a leading cause of irreversible blindness) that we have discovered using NGS techniques in an attempt towards translational research from bench to bedside to community.

Dr. Chakrabarti is Associate Director-Research at LVPEI, Hyderabad. Meet Dr. Chakrabarti on November 1, 2017, in Mumbai, India at Emerging Role of Next Generation Sequencing in Clinical Genomics.

Ethnicity and Breast Cancer Risk: The Indian Saga & Role of NGS

Conference Talk by Dr. Ahmad

IMG_1506 (1)
Dr. Firoz Ahmad 
Research Scientist & Senior Manager-R&D,SRL Diagnostics

Talk Abstract: Carcinoma of the breast is one of the most prevalent cancers in Indian females, and the incidence of breast cancer has been increasing manifolds in India and so the burden of breast cancer on the Indian healthcare system has been steadily on rising also emphasizing the need for a cost-effective method for early detection of these cancers.

Unfortunately, it has been established that Indian patients develop breast cancer at a younger age than their Caucasian counterparts, the contributions of BRCA1 and BRCA2 (BRCA1/2) mutations in Indians are expected to be different than in Caucasians. Although identification of BRCA1 and BRCA2 has greatly increased our understanding of breast cancer genetics in populations of Western European descent, reports about the role of these genes in Indian patients are still very limited. In the current report results found by using next-generation sequencing (NGS) tools, the prevalence and distribution pattern of BRCA1/2 gene mutations in Indian patients will be discussed, this presentation also aims to present the current status of knowledge about the spectrum of BRCA pathogenic variants in Indian populations.The study highlights how Next-generation sequencing (NGS) based testing increases the sensitivity of mutation detection, and help in identifying patients at high risk of developing cancer. New advances in genomic technologies, such as next-generation sequencing (NGS), allow the sequencing and analysis of genes associated with a disease/cancer efficiently at a significantly lower cost as compared with the traditional methods.

Studies such as these will provide physicians and researchers much-needed evidence on the clinical utility of NGS for incorporation into routine genetic testing in clinical oncology practice and thrust the clinical research.

Meet Dr. Firoz Ahmad at Emerging Role of Next Generation Sequencing in Clinical Genomics in Mumbai on November 01, 2017.

 

Histone Acetyltransferase Inhibitors, From Screening to Optimization – A Tricky Track

Conference Talk by Dr Baell

jonathan baell
Jonathan Baell Professor of Medicinal Chemistry (MIPS), Monash University Australia

Talk Abstract: There is currently great interest in compounds that modulate epigenetics. With respect to some epigenetic targets, such as histone decacetylases (HDACs), many inhibitors have been successfully developed and are in clinical trials for a variety of indications. Similarly, bromodomains have been shown, somewhat unexpectedly by some, to be highly druggable. However, there is an elephant in the room, and that is the histone acetyltransferase (HAT) family, which is large but essentially “undrugged” and barely has any compounds that could be considered to be useful tools. Why is it so hard to find good tool compounds for these enzymes?

Not so long ago we undertook HTS against a MYST HAT and eventually discovered a genuine hit that we have recently just optimized to nanomolar levels of inhibition. However, we encountered many problems en route. In this talk we will discuss such issues and how these could help explain why there are so few, if any, useful tool compounds for these enzymes.

Grab the chance to get in touch with Dr Jonathan Baell, from Monash University, Australia at SELECTBIO MedChem 2017” meeting on 14- 15 September, 2017 at Hotel Le Meridien, Bengaluru.